Breast Cancer Therapeutics Market Size to Reach US$ 63.9 Billion by 2030, Driven by Innovations and Growing Demand, Says The Insight Partners
The global breast cancer therapeutics market is expected to grow from US$ 31.07 billion in 2022 to US$ 63.9 billion by 2030, ...
CURE4d
Ongoing Trials Aim to Advance HER2-Negative Breast Cancer Treatment
Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...
Targeted Oncology2d
Understanding the Significance of ESR1 Mutations in Breast Cancer
Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...
CURE6d
Dr. Kevin Kalinsky Covers Targeted Therapy in HER2– Breast Cancer
Dr. Kevin Kalinsky discusses the role of targeted therapy and clinical decision-making in managing estrogen-driven, ...
Pharmabiz2h
Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer
Daiichi Sankyo launches Datroway in Japan for patients with previously treated unresectable or recurrent HR positive, HER2 negative breast cancer: Tokyo Thursday, March 20, 2025, ...
PR Newswire6d
VERZENIO's Market Potential Soars as Demand for CDK4/6 Inhibitors Grows | DelveInsight
In combination with an aromatase inhibitor as the initial endocrine-based therapy for adults with HR+/HER2- advanced or metastatic breast cancer. In combination with fulvestrant for adults with ...
DelveInsight Business Research, LLP: VERZENIO's Market Potential Soars as Demand for CDK4/6 Inhibitors Grows | DelveInsight
As VERZENIO gains traction in early-stage treatments and broadens its approved uses, its revenue is expected to keep growing. While the global CDK4/6 inhibitor market remains highly competitive ...
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the ...
Le Lézard1h
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, today announced new findings on golidocitinib, a ...